Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | KIT exon17 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05366816 | Phase II | Regorafenib Sunitinib | ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST | Recruiting | USA | 0 |
NCT06087263 | Phase II | Regorafenib | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. | Recruiting | USA | 0 |
NCT05609942 | Phase Ib/II | Elenestinib Azacitidine + Elenestinib | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) | Recruiting | USA | NOR | NLD | FRA | ESP | DEU | BEL | 0 |
NCT02638766 | Phase II | Regorafenib | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI) | Completed | ITA | FRA | ESP | 0 |